Clinical Trials Sponsored by Solta Medical

Total 55379 results

Solta Medical

Completed

Evaluation of Procedural Analgesia for Liposonix Treatment

Body Contouring

United States
Solta Medical

Completed

Evaluation of a Photopneumatic System for the Treatment of Acne

Mild to Moderate Acne

United States
Solta Medical

Completed

Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method

Subcutaneous Adipose Tissue

United States
Solta Medical

Completed

Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound

Treatment of Adipose Tissue in the Thighs

United States, Canada
Volta Medical

Active, not recruiting

Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion (RESTART)

Atrial Fibrillation

United States, France, Belgium
Volta Medical

Completed

AutoMatic disPERsion Tagging Function Preliminary Evaluation (AMPERE)

Atrial Fibrillation | Atrial Tachycardia | Atrial Arrhythmia

France
Volta Medical
Fortrea

Recruiting

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation (COMRADE-AI)

Atrial Fibrillation | Arrhythmias, Cardiac | Atrial Arrhythmia

France
Milton S. Hershey Medical Center
Solta Medical

Withdrawn

Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing

Pain

United States
Volta Medical
Covance; CardiaBase

Completed

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation (Tailored-AF)

Atrial Fibrillation

United States, Germany, Belgium, France, Netherlands
UnionDerm
Skin of Color Society; Solta Medical; Scientis

Recruiting

Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

Melasma

United States
Unimed Volta Redonda

Unknown

Sepse: Critical Analysis of New Sepse Definitions and Retrospective Evaluation of Sepse Protocol at a Tertiary Hospital in Brazil (HUVR)

Sepsis

Brazil
Centro Cardiovascular Salta

Unknown

Dextran Use for Primary Angioplasty Protection in Acute Myocardial Infarction (DUPAP)

Acute Myocardial Infarction With ST Elevation
Siolta Therapeutics, Inc.

Active, not recruiting

Allergic Disease Onset Prevention Study (adored)

Atopic Dermatitis | Type 1 Hypersensitivity

United States, Australia, Puerto Rico
Lorraine Hickson
Bausch Health Americas, Inc.; Solta Medical

Completed

Bausch Health Thermage FXL for Use on Lower Face and Submentum Area

Skin Wrinkling

United States
Siolta Therapeutics, Inc.
Integrium

Unknown

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Atopic Immunoglobulin E-Mediated Allergic Disorder

United States
Catholic University of Salta

Completed

Vitamin K2 Supplementation and Vascular Calcification

Renal Disease
Volta Medical
Heart Rhythm Clinical and Research Solutions, LLC

Not yet recruiting

Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation (COMPANION AI)

Atrial Fibrillation
SOLTI Breast Cancer Research Group

Recruiting

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain
Wesameldin Abelrahman Soltan

Recruiting

Role of Ultrasound Assessment of Parasternal Intercostal Muscle Thickness During Weaning From Mechanical Ventilation

Weaning From Mechanical Ventilation | Parasternal Intercostal Muscle Thickness

Egypt
SOLTI Breast Cancer Research Group

Terminated

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA)

Breast Cancer

Spain, Portugal
Clinica las Condes, Chile
Solta Medical; Corporacion de ayuda al niño quemado (COANIQUEM)

Unknown

Fractional Photothermolysis for the Treatment of Burn Scars

Scar

Chile
SOLTI Breast Cancer Research Group

Completed

SOLTI Breast Cancer Molecular Screening Program (AGATA) (AGATA)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (ARIANNA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
Ayca Solt Kirca

Completed

Stria Gravidarum and Olive Oil for Pregnancy Women

Pregnancy Related | Striae Gravidarum

Turkey
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Pfizer

Completed

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (PROMETEO II)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Completed

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. (CORALLEEN)

Breast Cancer

Spain
Sanofi
SOLTI Breast Cancer Research Group

Completed

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)

Breast Cancer Female

Spain, France, Germany
Universidad Nacional de Salta
Fundacion Mundo Sano

Not yet recruiting

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Pharmacological Action
SOLTI Breast Cancer Research Group
Novartis; UNICANCER

Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

Breast Cancer Stage II

Spain, France, Portugal
SOLTI Breast Cancer Research Group
Eisai Inc.

Completed

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

Breast Cancer

Spain, France, Portugal, Germany
SOLTI Breast Cancer Research Group
Schering-Plough

Completed

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)

Breast Cancer

Spain
Genentech, Inc.
SOLTI Breast Cancer Research Group

Completed

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Breast Cancer

United States, Spain, Portugal
Helse Stavanger HF
Universidad Católica de Salta

Completed

ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study (ARRA-RACS)

Myocardial Infarction | Coronary Artery Disease | Chest Pain | Unstable Angina Pectoris

Norway, Argentina
Oncolytics Biotech
SOLTI Breast Cancer Research Group

Terminated

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

Breast Cancer

Spain
Fundacio Clinic Barcelona
SOLTI Breast Cancer Research Group

Not yet recruiting

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001)

Metastatic Triple-Negative Breast Carcinoma

Spain
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (ATREZZO)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Daiichi Sankyo, Inc.

Active, not recruiting

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Pierre Fabre Laboratories

Completed

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Daiichi Sankyo, Inc.

Active, not recruiting

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Radius Health, Inc.

Completed

Elacestrant in Preoperative Setting, a Window of Opportunity Study (ELIPSE)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma

Spain
University of California, San Diego
Haus of Volta

Completed

Physical Activity Intervention for Young Cancer Survivors

Quality of Life | Breast Cancer | Physical Activity

United States
SOLTI Breast Cancer Research Group
Sysmex America, Inc.

Completed

Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer (SOLO-1)

Breast Cancer

Spain

Clinical Trials Sponsored by Solta Medical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations